Samsung Biologics Co.,Ltd. EBIT Margin for the year ending December 31, 2024: 31.17%

Samsung Biologics Co.,Ltd. EBIT Margin is 31.17% for the year ending December 31, 2024, a -4.20% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Samsung Biologics Co.,Ltd. EBIT Margin for the year ending December 31, 2023 was 32.54%, a -6.63% change year over year.
  • Samsung Biologics Co.,Ltd. EBIT Margin for the year ending December 31, 2022 was 34.85%, a -2.80% change year over year.
  • Samsung Biologics Co.,Ltd. EBIT Margin for the year ending December 31, 2021 was 35.85%, a 39.26% change year over year.
  • Samsung Biologics Co.,Ltd. EBIT Margin for the year ending December 31, 2020 was 25.74%, a 67.06% change year over year.
Key Data
Date EBIT Margin EBITDA Margin Net Income Margin EBT Margin